Table 1.

Patient characteristics

	Expansion cohort (N=26)	Escalation cohorts (N=22)	All patients (N=48)
	n (%)	n (%)	n (%)
Age, years [mean (SD)]	57 (11)	54 (10)	56 (11)
Gender
Female	16 (62%)	13 (59%)	29 (60%)
Male	10 (38%)	9 (41%)	19 (40%)
Diagnosis
Colorectal	14 (54%)	7 (32%)	21 (44%)
Melanoma	0 (0%)	7 (32%)*	7 (15%)
Ovarian	1 (4%)	2 (9%)	3 (6%)
Breast	1 (4%)	1 (5%)	2 (4%)
Cholangiocarcinoma	2 (8%)	0 -	2 (4%)
Other**	8 (32%)	5 (25%)	13 (27%)
ECOG PS
0	7 (27%)	10 (45%)	17 (35%)
1	18 (69%)	12 (55%)	30 (63%)
2	1 (4%)	0 -	1 (2%)
Number of prior therapies [mean (SD)]	4 (3)	3 (2)	4 (2)

^*expansion versus escalation cohort, p=0.003

^**“Other” includes adenocarcinoma of the duodenum, cervical cancer, cholangiocarcinoma combined with hepatocellular carcinoma, hepatocellular carcinoma, gastric cancer, hemangioperycitoma, neuroendocrine cancer, pancreatic cancer, prostate cancer, small cell lung cancer, and unknown primary.

SD = standard deviation; ECOG = Eastern Cooperative Oncology Group; PS = performance status